AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17201801 — intervention group
Group type: EXPERIMENTAL
Intervention: 72-hour fasting (without leptin administration)
Number of subjects: 6
Study 17201801 — intervention group
Group type: COMPARATOR
Intervention: Baseline fed state (control study)
Number of subjects: 6
Study 15488878 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100mg
Number of subjects: 122
Study 15488878 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg
Number of subjects: 122
Study 15488878 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg
Number of subjects: 122
Study 15488878 — intervention group
Group type: EXPERIMENTAL
Intervention: All ARBs (Losartan, Irbesartan, Candesartan)
Number of subjects: 122
Study 15488878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 11226112 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg
Number of subjects: 225
Study 11226112 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg
Number of subjects: 225
Study 11226112 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 2.5 mg
Number of subjects: 225
Study 11226112 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg
Number of subjects: 225
Study 11226112 — intervention group
Group type: COMPARATOR
Intervention: Saline 2 mL
Number of subjects: 225
Study 9773696 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block of the ipsilateral nerve roots of T12, L1, and L2
Number of subjects: 30
Study 9773696 — intervention group
Group type: COMPARATOR
Intervention: Field block
Number of subjects: 30
Study 8144341 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic contrast media iohexol
Number of subjects: 20
Study 8144341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic contrast media ioxaglate
Number of subjects: 20
Study 3276279 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (500 mg/d)
Number of subjects: 32
Study 3276279 — intervention group
Group type: COMPARATOR
Intervention: Oxprenolol (80 mg/d)
Number of subjects: 32
Study 3276279 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa after switching from Oxprenolol
Number of subjects: 32
Study 3276279 — intervention group
Group type: COMPARATOR
Intervention: Oxprenolol after switching from Methyldopa
Number of subjects: 32
Study 31657167 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with repetitive transcranial magnetic stimulation
Number of subjects: 220
Study 31657167 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation training and repetitive transcranial magnetic stimulation (Control)
Number of subjects: 220
Study 28279854 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-attainment-theory-based education program
Number of subjects: 64
Study 28279854 — intervention group
Group type: COMPARATOR
Intervention: Routine management (Control)
Number of subjects: 64
Study 25413223 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 61
Study 25413223 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 61
Study 23305192 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 294
Study 21777999 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic foot with decreased stiffness
Number of subjects: 12
Study 18482454 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg elemental iron (as ferrous fumarate) multivitamin
Number of subjects: 167
Study 18482454 — intervention group
Group type: COMPARATOR
Intervention: 60 mg elemental iron (as ferrous sulphate) multivitamin
Number of subjects: 167
Study 16169655 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available composite surface sealers
Number of subjects: 0
Study 16169655 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin-bonding agent
Number of subjects: 0
Study 16169655 — intervention group
Group type: COMPARATOR
Intervention: Composite surface sealers
Number of subjects: 0
Study 14643940 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-Step counseling condition
Number of subjects: 252
Study 14643940 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral counseling condition
Number of subjects: 252
Study 14643940 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial hospitalization setting
Number of subjects: 252
Study 14643940 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient setting
Number of subjects: 252
Study 14643940 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help affiliation
Number of subjects: 252
Study 14643940 — intervention group
Group type: EXPERIMENTAL
Intervention: High-severity patients
Number of subjects: 252
Study 14643940 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-severity patients
Number of subjects: 252
Study 11113718 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (maintenance dose 89±11 mg/day, range 50-100 mg/day)
Number of subjects: 100
Study 11113718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11113718 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 100
Study 9352289 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive control function (measured by EXIT25 and MMSE)
Number of subjects: 105
Study 9352289 — intervention group
Group type: EXPERIMENTAL
Intervention: Discriminant model based on EXIT25 and MMSE scores
Number of subjects: 105
Study 9352289 — intervention group
Group type: COMPARATOR
Intervention: Probable Alzheimer's disease patients
Number of subjects: 105
Study 9352289 — intervention group
Group type: COMPARATOR
Intervention: Institutionalized elderly retirees
Number of subjects: 105
Study 9352289 — intervention group
Group type: COMPARATOR
Intervention: Noninstitutionalized retirees
Number of subjects: 105
Study 8474401 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline oxide (60 mg)
Number of subjects: 24
Study 8474401 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine (50 mg)
Number of subjects: 24
Study 8474401 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline oxide and trimipramine
Number of subjects: 24
Study 8474401 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects assessment
Number of subjects: 24
Study 3776446 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular oxycodone on request following an intraoperative intercostal block (Group C)
Number of subjects: 51
Study 3776446 — intervention group
Group type: COMPARATOR
Intervention: Intercostal blocks with 0.5% bupivacaine (Group IC)
Number of subjects: 51
Study 3776446 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine as a continuous infusion of 0.25% bupivacaine (Group EB)
Number of subjects: 51
Study 3776446 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 4 mg injected prior to surgery and on the first postoperative morning (Group EM4)
Number of subjects: 51
Study 3776446 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 6 mg injected prior to surgery and on the first postoperative morning (Group EM6)
Number of subjects: 51
Study 29529169 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC + AAP (abiraterone acetate 1000 mg + prednisolone 5 mg daily)
Number of subjects: 566
Study 29529169 — intervention group
Group type: COMPARATOR
Intervention: SOC + DocP (docetaxel 75 mg/m2 3-weekly x 6 + prednisolone 10 mg daily)
Number of subjects: 566
Study 29529169 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC + AAP
Number of subjects: 566
Study 29529169 — intervention group
Group type: COMPARATOR
Intervention: SOC + DocP
Number of subjects: 566
Study 27993759 — intervention group
Group type: EXPERIMENTAL
Intervention: app+counseling
Number of subjects: 833
Study 27993759 — intervention group
Group type: COMPARATOR
Intervention: counseling only
Number of subjects: 833
Study 24797189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Functional (Cog-Fun) intervention
Number of subjects: 19
Study 24797189 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 19
Study 23190359 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) with creatine and protein supplementation
Number of subjects: 30
Study 23190359 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) group undergoing identical PRT protocol with placebo supplementation
Number of subjects: 30
Study 19875232 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 158
Study 19875232 — intervention group
Group type: COMPARATOR
Intervention: Pain Clinic treatment
Number of subjects: 158
Study 19875232 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 158
Study 18160741 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone antagonist plus testosterone administration for 4 weeks
Number of subjects: 0
Study 18160741 — intervention group
Group type: COMPARATOR
Intervention: Progestogen treatment
Number of subjects: 0
Study 16177164 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide treatment (NO); N2O and EMLA
Number of subjects: 70
Study 16177164 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CO); cutaneous application of EMLA
Number of subjects: 70
Study 16177164 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide treatment (NO)
Number of subjects: 70
Study 16177164 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide treatment (NO) and Conventional treatment (CO)
Number of subjects: 70
Study 12709682 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (1 g/kg/min during CPB)
Number of subjects: 30
Study 12709682 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 30
Study 11128561 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 400 mg/day i.m. for a minimum of 4 months
Number of subjects: 76
Study 11128561 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 200 mg/day i.m. (reduced dose for 2 patients)
Number of subjects: 76
Study 11128561 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin treatment
Number of subjects: 76
Study 8793451 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 ppm NO2 in ambient air
Number of subjects: 20
Study 8793451 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 ppm NO2 in ambient air
Number of subjects: 20
Study 8793451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient air + combustion by-products + 0.3 ppm NO2
Number of subjects: 20
Study 8793451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient air + combustion by-products + 0.6 ppm NO2
Number of subjects: 20
Study 8793451 — intervention group
Group type: COMPARATOR
Intervention: Ambient air (control)
Number of subjects: 20
Study 1621789 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% epinephrine
Number of subjects: 0
Study 1621789 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% dipivefrin
Number of subjects: 0
Study 1621789 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% epinephrine with nasolacrimal occlusion
Number of subjects: 0
Study 1621789 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% epinephrine with and without nasolacrimal occlusion
Number of subjects: 0
Study 1621789 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% dipivefrin every 12 hours
Number of subjects: 0
Study 6388897 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin (2 g/day)
Number of subjects: 25
Study 6388897 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin plus Niacin (3 g/day)
Number of subjects: 25
Study 6388897 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with Neomycin plus Niacin
Number of subjects: 25
Study 6388897 — intervention group
Group type: COMPARATOR
Intervention: Diet-only therapy
Number of subjects: 25
Study 6388897 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined regimen compliance
Number of subjects: 25
Study 31402718 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (NAPSO) 440 mg
Number of subjects: 385
Study 31402718 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (IBU) 400 mg
Number of subjects: 385
Study 31402718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study 27553214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80mg every 2 weeks (IXEQ2W)
Number of subjects: 417
Study 27553214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80mg every 4 weeks (IXEQ4W)
Number of subjects: 417
Study 27553214 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40mg every 2 weeks
Number of subjects: 417
Study 27553214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 27553214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (both regimens)
Number of subjects: 417
Study 26573022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftobiprole 500 mg, administered by 2-hour intravenous infusion every 8 hours.
Number of subjects: 0
Study 26573022 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime/linezolid
Number of subjects: 0
Study 26573022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Number of subjects: 0
Study 27129122 — intervention group
Group type: EXPERIMENTAL
Intervention: PRTX-100 (0.15, 0.45, 0.90, or 1.50 µg/kg)
Number of subjects: 0
Study 27129122 — intervention group
Group type: EXPERIMENTAL
Intervention: PRTX-100
Number of subjects: 0
Study 27129122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22959335 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning (4 doses of 2 Gy total-body irradiation and 150 mg/m² fludarabine)
Number of subjects: 195
Study 22959335 — intervention group
Group type: COMPARATOR
Intervention: Standard conditioning (6 doses of 2 Gy total-body irradiation and 120 mg/kg cyclophosphamide)
Number of subjects: 195
Study 22959335 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning
Number of subjects: 195
Study 22959335 — intervention group
Group type: COMPARATOR
Intervention: Standard conditioning
Number of subjects: 195
Study 20214336 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaomi granules (XMG)
Number of subjects: 40
Study 20214336 — intervention group
Group type: COMPARATOR
Intervention: Anticandine (Control)
Number of subjects: 40
Study 18156036 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 inhibitors (rofecoxib, celecoxib, sulindac, meloxicam, indometacin) with low-dose aspirin
Number of subjects: 0
Study 18156036 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 inhibitors with low-dose aspirin
Number of subjects: 0
Study 18156036 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 inhibitors (celecoxib, rofecoxib) with low-dose aspirin
Number of subjects: 0
Study 18156036 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 inhibitors
Number of subjects: 0
Study 18156036 — intervention group
Group type: COMPARATOR
Intervention: Non-selective NSAIDs with low-dose aspirin
Number of subjects: 0
Study 15074088 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Banxia Houpu Decoction (MBHD) in treated group A
Number of subjects: 187
Study 15074088 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Banxia Houpu Decoction (MBHD) in treated group B
Number of subjects: 187
Study 15074088 — intervention group
Group type: COMPARATOR
Intervention: Imitate preparation in control group
Number of subjects: 187
Study 16098301 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography with real-time low mechanical index perfusion imaging (using intravenous Optison)
Number of subjects: 27
Study 16098301 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine stress echocardiography without real-time perfusion imaging (high mechanical index harmonic imaging)
Number of subjects: 27
Study 16098301 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time perfusion imaging
Number of subjects: 27
Study 10332666 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet combined with aerobic exercise (DA)
Number of subjects: 29
Study 10332666 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet combined with resistance exercise (DR)
Number of subjects: 29
Study 10332666 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (DO)
Number of subjects: 29
Study 8743516 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca antagonists
Number of subjects: 22
Study 8743516 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 22
Study 1656826 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous foscarnet at a dose of 60 mg/kg body weight three times a day for 3 weeks followed by 90 mg/kg once a day (treatment group)
Number of subjects: 24
Study 1656826 — intervention group
Group type: COMPARATOR
Intervention: No therapy (delayed treatment, control group)
Number of subjects: 24
Study 1656826 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous foscarnet treatment
Number of subjects: 24
Study 1656826 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 1656826 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet treatment
Number of subjects: 24
Study 1656826 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 24
Study 7042113 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4524
Study 7042113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4524
Study 7042113 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of Q waves
Number of subjects: 4524
Study 7042113 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent Q waves in a single infarct location
Number of subjects: 4524
Study 7042113 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple electrocardiographic infarct locations
Number of subjects: 4524
Study 30951586 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based behavioral skills treatment
Number of subjects: 181
Study 30951586 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management with voucher-based reinforcement
Number of subjects: 181
Study 30951586 — intervention group
Group type: COMPARATOR
Intervention: Continued skills without contingency management
Number of subjects: 181
Study 30951586 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued skills for younger adolescents
Number of subjects: 181
Study 29261566 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation-related cardiac arrest
Number of subjects: 1847
Study 26768099 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary node sampling (ANS)
Number of subjects: 799
Study 26768099 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary node sampling (ANS) + axillary radiotherapy (AXRT)
Number of subjects: 799
Study 25480930 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise (MICE) at 50% HRR for 25 min
Number of subjects: 34
Study 25480930 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Intermittent Exercise (HIIE) at 100% HRR for 30s followed by 30s rest for 25 min
Number of subjects: 34
Study 25480930 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise group
Number of subjects: 34
Study 22648790 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 4 Hz (200 mJ, 12 mm, 20 s)
Number of subjects: 60
Study 22648790 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 6 Hz (200 mJ, 12 mm, 20 s)
Number of subjects: 60
Study 22648790 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 10 Hz (200 mJ, 12 mm, 20 s)
Number of subjects: 60
Study 22648790 — intervention group
Group type: EXPERIMENTAL
Intervention: All frequencies (4, 6, 10 Hz) on sound dentin
Number of subjects: 60
Study 22648790 — intervention group
Group type: EXPERIMENTAL
Intervention: All frequencies (4, 6, 10 Hz) on carious dentin
Number of subjects: 60
Study 20810101 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 123
Study 20810101 — intervention group
Group type: COMPARATOR
Intervention: Maintenance antidepressants (mADM)
Number of subjects: 123
Study 18253048 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 100
Study 18253048 — intervention group
Group type: COMPARATOR
Intervention: Non-Eicosapentaenoic acid (non-EPA)
Number of subjects: 100
Study 15757007 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient relapse prevention (RP) program
Number of subjects: 0
Study 15757007 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated prison control groups)
Number of subjects: 0
Study 15757007 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient relapse prevention (RP) program (treatment goal met)
Number of subjects: 0
Study 15757007 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient relapse prevention (RP) program (treatment goal not met)
Number of subjects: 0
Study 11882751 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 121
Study 11882751 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 121
Study 10048703 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine
Number of subjects: 0
Study 10048703 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 0
Study 7541435 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol (2 g every 6 hr)
Number of subjects: 60
Study 7541435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31299655 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiopronin (3 g daily for up to 14 days after aSAH)
Number of subjects: 60
Study 31299655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28237759 — intervention group
Group type: EXPERIMENTAL
Intervention: Center for Epidemiological Studies – Depression Scale (CES-D)
Number of subjects: 91
Study 28237759 — intervention group
Group type: EXPERIMENTAL
Intervention: CES-D
Number of subjects: 91
Study 25904586 — intervention group
Group type: EXPERIMENTAL
Intervention: Particle-filtered air (PM2.5 levels of 3 µg/m(3))
Number of subjects: 60
Study 25904586 — intervention group
Group type: COMPARATOR
Intervention: Sham-filtered air (PM2.5 levels of 24 µg/m(3))
Number of subjects: 60
Study 25904586 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to PM from urban street air
Number of subjects: 60
Study 23552179 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion
Number of subjects: 195